Connection

Jeffrey Jones to Protein Kinase Inhibitors

Back to Details
This is a "connection" page, showing publications Jeffrey Jones has written about Protein Kinase Inhibitors.
Jeffrey Jones
Connection Strength
0.657
Protein Kinase Inhibitors
  1. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. 2018 01; 19(1):65-75.
    View in: PubMed
    Score: 0.487
  2. Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia. JAMA Oncol. 2015 Apr; 1(1):80-7.
    View in: PubMed
    Score: 0.101
  3. Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J Clin Oncol. 2009 Dec 10; 27(35):6012-8.
    View in: PubMed
    Score: 0.069
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.